Bio-Techne has solidified its position as a "picks and shovels" provider for the biotechnology industry, ensuring that researchers have the high-quality proteins and antibodies necessary for reproducible science. The company operates a portfolio exceeding 500,000 products with over 3,100 employees across 34 locations worldwide and serves end markets such as pharmaceuticals, biotechnology, academia, and diagnostics.
Cyborg Score Rationale
The company achieved 5% organic revenue growth to approximately $1.22 billion in fiscal year 2025, with Q2 FY2025 showing 9% organic revenue increase and adjusted EPS of $0.42, driven by strong performance in cell therapy and proteomic analysis. Core positioning in critical life sciences infrastructure provides resilience despite macro headwinds.
Top Insights
Strong market position as essential supplier of reagents and diagnostic tools critical to drug discovery and clinical diagnostics workflows
Diversified customer base across pharmaceutical, biotechnology, academic research, and clinical diagnostics reduces concentration risk
Organic growth of 5-9% in fiscal year 2025 reflects resilience despite macroeconomic volatility
Cell therapy and proteomic analysis represent high-growth segments within core Protein Sciences and Diagnostics & Spatial Biology divisions
Named Competitors
Invitrogen/Applied Biosystems — Life sciences reagents and instruments
MilliporeSigma — Laboratory chemicals and reagents
Abcam — Antibodies and research reagents
Recent Developments
(January 2026) CEO presentation at J.P. Morgan Healthcare Conference
(Fiscal Year 2025) Achieved $1.22 billion in net sales with 5% organic revenue growth
Open the full interactive Bio-Techne Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.